Ninety‐Day Readmission and Morbidity Following Liver Transplantation for MASLD
Despite an increased comorbid risk profile, MASLD LT recipients had superior 90-day readmission rates and morbidity outcomes relative to non-MASLD LT recipients. MASLD etiology appears to normalize 90-day outcomes among patients with obesity and liver cancer.
Authors
- S IKRAMUDDIN
- Eric S. Wise (ORCID: https://orcid.org/0000-0002-6471-9466)
- Thomas M. Leventhal (ORCID: https://orcid.org/0000-0002-6646-4487)
- Sean Huu-Tien Nguyen
- Raja Kandaswamy
- Zachary Leslie
- David Leishman
- Abraham J. Matar
- Cheyenna Espinoza
Institutions
- University of Minnesota (US)
- Carleton College (US)
Publication Details
- Journal
- Clinical Transplantation
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1111/ctr.70461
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00